• Users Online: 380
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2017  |  Volume : 37  |  Issue : 2  |  Page : 43-48

Effectiveness and safety of fexofenadine in chronic idiopathic urticaria − open-label noncomparative study in daily practice

Dermatology and Venerology Department, Alex University, Alex, Egypt

Correspondence Address:
Magdy Ragab
Dermatology and Venerology Department, Alex University, 28 alt Basha Zolfakar Roshdy Alex
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ejdv.ejdv_38_16

Rights and Permissions

Objective This study aimed to evaluate effectiveness and safety of fexofenadine in the treatment of chronic idiopathic urticaria (CIU) in routine practice in Egypt. Patients and methods This study is a local, multicenter, noninterventional, prospective, open-label, noncomparative, observational product registry conducted across Egypt. Three mandatory visits were made by the investigator for each eligible patient, and patients were assessed by urticaria symptoms score. Result The results of this study showed a statistically significant reduction (P<0.001) in signs and symptoms of CIU evaluated by the urticaria-related signs and symptoms score according to patients’ completed diary cards. Pruritis was decreased in 74.9% of patients and was improved in 22.3% of patients. Hives were relieved in 81.1% of patients and were improved in 17.5% of patients, whereas other related signs and symptoms of CIU were decreased in 75.5% of patients and improved in 22.2% of patients. Mild dizziness was reported in 0.2% of total enrolled patients that recovered after 3 days without corrective treatment. Conclusion Fexofenadine demonstrated statistically significant reduction in symptoms and signs of CIU. Pruritis status was decreased in 74.95% of patients. Hives status were relieved in 81.1% of patients, after a mean treatment duration of 14.93±5.49 days at visit 2 and 27.94±4.56 days at visit 3 (end of study). In addition, treatment with fexofenadine was well tolerated.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded407    
    Comments [Add]    

Recommend this journal